<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53756">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02053831</url>
  </required_header>
  <id_info>
    <org_study_id>CP-1040</org_study_id>
    <nct_id>NCT02053831</nct_id>
  </id_info>
  <brief_title>GalaFlex Mesh in Facelift</brief_title>
  <official_title>GalaFlex Mesh in Facelift</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galatea, Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galatea, Corp</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this post market study a resorbable mesh (GalaFLEX) will be used to reinforce the lifted
      and imbricated SMAS along the suture lines and spread the load of the SMAS along a greater
      surface area.  GalaFLEX mesh is comprised of resorbable 4-hydroxybutyrate fibers.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Physician Satisfaction</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigator satisfaction will be judged by ease of product use, successful reinforcement, and total time for procedure to be completed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient satisfaction will be judged by the difference between pre- and post-surgery answers to Quality of Life questionnaires.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">15</enrollment>
  <condition>Superficial Musculoaponeurotic System (SMAS) Procedure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able to understand the risks and benefits of participating in the study
             and must be willing to sign and date the Informed Consent Form for this study
             approved by the Institutional Review Board (IRB.)

          -  Be at least 21 years of age.

          -  Be willing and able to comply with the requirements of the protocol.

          -  Be willing to refrain from participating in any other investigational interventional
             study while enrolled in this study.

          -  Female subjects must have a negative pregnancy test within the last 24 hours timeline
             and have no intentions of becoming pregnant during participation in the study, or be
             sterilized.

        Exclusion Criteria:

          -  Subject is unwilling or unable to give written consent to participate in the
             investigation or unable to comply with the requirements of the protocol.

          -  Subject has  known severe allergies manifested by a history of anaphylaxis, or
             history or presence of severe multiple allergies.

          -  Subject has any serious skin disease, e.g., Eczema and psoriasis of the face, severe
             rosacea, scleroderma, local infections and severe acne.

          -  Subjects has diabetes, coagulation disorders, connective tissue disorders,
             lipodystrophy, or other serious systemic disease.

          -  Active herpes labialis

          -  Subject is infected with HIV and/or received or may receive immunosuppressive therapy
             over the course of the study (such as rheumatoid arthritis).

          -  Received any experimental drug or device within the previous three months.

          -  Known alcohol or drug abuser.

          -  Female subject who is pregnant or lactating or intending to become pregnant during
             the period of the study, or who would not use an adequate method of contraception
             (contraceptive pill, intra-uterine device) for the duration of the study.

          -  Possesses any psychological condition, or is under treatment for any condition which,
             in the opinion of the Investigator and/or consulting physicians(s),would constitute
             an unwarranted risk.

          -  Presents with severe jowling or severe cervical skin redundancy.

          -  Subject is currently a smoker or is a prior smoker who quit in the last 12 months.

          -  Active abscess or infection

          -  Currently involved with claims for, or is accepting, workers compensation

          -  Currently engaged in medical malpractice litigation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arikha Moses, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Chief Scientific Officer, Founder</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ponte Vedra Plastic Surgery</name>
      <address>
        <city>Ponte Vedra Beach</city>
        <state>Florida</state>
        <zip>32083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye and Ear Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Few Institute for Aesthetic Plastic Surgery</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 31, 2014</lastchanged_date>
  <firstreceived_date>January 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plastic surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
